Last updated: August 27, 2026
Miraluma is the former brand name for technetium Tc 99m sestamibi, a kit-based radiopharmaceutical used primarily for myocardial perfusion imaging and, historically, breast imaging. Its commercial trajectory is mature and largely genericized. The product no longer has meaningful brand-driven exclusivity, standalone revenue is not publicly disclosed, and economic value has shifted from Miraluma branding to hospital supply contracts, radiopharmacy distribution, technetium availability and broader cardiac-imaging portfolios.
What is Miraluma and how is it used?
Miraluma is a technetium Tc 99m sestamibi diagnostic imaging product. The active imaging complex is prepared by reconstituting a nonradioactive kit with technetium-99m pertechnetate before administration.
Its principal uses are:
| Use |
Clinical role |
Commercial status |
| Myocardial perfusion imaging |
Detection and assessment of coronary artery disease |
Main continuing market |
| Breast imaging |
Adjunctive imaging for selected breast-lesion evaluation |
Niche use |
| Diagnostic nuclear medicine |
Hospital and outpatient imaging procedures |
Established, mature market |
Miraluma was associated with breast imaging, while the same sestamibi technology was commercialized under the Cardiolite brand for cardiac imaging. The distinction mattered commercially because cardiac nuclear medicine generated the larger and more durable procedure base.
The U.S. Food and Drug Administration approved technetium Tc 99m sestamibi products for myocardial perfusion imaging and breast imaging through separate labeling and regulatory histories. The FDA labeling describes the product as a radiopharmaceutical kit requiring preparation by qualified nuclear medicine personnel.[1]
Who owned Miraluma and how did its commercial position change?
The product originated within DuPont Pharmaceuticals and became part of Bristol-Myers Squibb after the companies combined their pharmaceutical operations. Bristol-Myers Squibb later sold its medical imaging business to Bracco, transferring the commercial infrastructure associated with Cardiolite and related imaging products.[2]
Ownership and commercialization timeline
| Period |
Commercial event |
Strategic impact |
| 1990s |
FDA approvals for technetium Tc 99m sestamibi imaging products |
Established cardiac and breast-imaging applications |
| 2001 |
Bristol-Myers Squibb completed its combination with DuPont Pharmaceuticals |
Consolidated ownership of the legacy product portfolio |
| 2002 |
Bracco acquired Bristol-Myers Squibb’s medical imaging business |
Moved the key commercial franchise into a specialized imaging company |
| 2000s |
Generic and alternative sestamibi supply expanded |
Reduced dependence on the original brand |
| 2010s onward |
Mature radiopharmaceutical market and broader imaging competition |
Shifted value toward distribution, reliability and procedure volume |
The most economically important brand in the portfolio became Cardiolite rather than Miraluma. Miraluma’s breast-imaging positioning did not develop into a comparable mass-market franchise because mammography, ultrasound and magnetic resonance imaging remained the dominant breast-imaging modalities.
What is the FDA regulatory status of Miraluma?
Miraluma is a conventional small-molecule radiopharmaceutical product, not a biologic. It is therefore subject to the drug approval and generic-drug framework rather than the biosimilar pathway.
The FDA regulatory profile includes:
- A prescription diagnostic imaging product.
- A radiopharmaceutical kit requiring extemporaneous preparation.
- Use of technetium-99m, whose availability depends on generator and isotope supply.
- Manufacturing controls covering kit composition, sterility, radiochemical purity and preparation instructions.
- Product-specific labeling for cardiac and breast imaging indications.
The commercial relevance of an individual brand depends on whether the FDA-approved product remains actively marketed, whether the application has been withdrawn or discontinued, and whether equivalent products are available. A former brand can retain historical recognition while losing practical market share to current sestamibi suppliers.
Does Miraluma have FDA exclusivity?
No meaningful FDA exclusivity remains. Any new-drug exclusivity associated with the original approvals expired many years ago. Miraluma is not protected by orphan-drug exclusivity, pediatric exclusivity or biologic reference-product exclusivity.
The relevant commercial pathway for competitors is an abbreviated new drug application or an equivalent radiopharmaceutical approval route, subject to FDA requirements for pharmaceutical equivalence, radiochemical performance, sterility and labeling.
What patents protect Miraluma?
Miraluma has no commercially significant active patent barrier based on the age of the product and the maturity of technetium Tc 99m sestamibi technology.
Patent estate assessment
| Patent category |
Current commercial relevance |
| Sestamibi composition patents |
Expired |
| Cardiac imaging method patents |
Expired or no longer exclusionary |
| Breast-imaging method patents |
Expired or commercially weak |
| Kit formulation patents |
Historical protection has expired |
| Manufacturing process patents |
May exist in isolated contexts but do not block routine generic supply |
| Radioisotope preparation know-how |
Operational barrier rather than Miraluma-specific patent protection |
The Orange Book is the relevant U.S. source for listed patents and regulatory exclusivity for approved drugs. Miraluma’s age, generic availability and absence of a current branded franchise indicate that Orange Book-listed intellectual property does not create a practical barrier to market entry.[3]
How strong is the Miraluma patent estate?
The patent estate is weak from a current commercial perspective.
Its remaining value is limited because:
- The core sestamibi technology has been available for decades.
- Cardiac imaging is served by multiple suppliers and alternative radiopharmaceuticals.
- Generic and contract radiopharmacy channels reduce dependence on the original brand.
- Patent expiry has moved competition toward manufacturing reliability and price.
- The principal supply constraint is access to technetium-99m and validated radiopharmacy operations, not molecule ownership.
When did Miraluma lose exclusivity?
Miraluma lost meaningful exclusivity during the 2000s as composition, formulation and use-related patent protection expired and alternative sestamibi products entered the market.
The loss of exclusivity was gradual rather than tied to a single modern Paragraph IV event. Radiopharmaceutical products often experience commercial erosion through hospital contracting, regional radiopharmacy substitution and supplier changes rather than through a single large generic launch.
Exclusivity timeline
| Exclusivity type |
Approximate status |
| Original FDA new-drug exclusivity |
Expired decades ago |
| Core composition patents |
Expired |
| Cardiac-use patent protection |
Expired |
| Breast-imaging protection |
Expired or commercially nonblocking |
| Current brand exclusivity |
None of practical significance |
| Biosimilar exclusivity |
Not applicable |
Are there Paragraph IV challenges to Miraluma?
Paragraph IV litigation is not the principal current risk for Miraluma. The product is too mature for a conventional branded-drug challenge to determine its economic outlook.
A Paragraph IV certification is relevant when an ANDA applicant challenges an unexpired Orange Book patent. For Miraluma, the key commercial issue is not whether a new entrant will invalidate a remaining patent. It is whether suppliers can meet FDA, state radiopharmacy, isotope-handling and hospital procurement requirements.
No current, economically material Paragraph IV dispute is central to the Miraluma market based on the product’s mature regulatory status and genericized supply base. Relevant historical patent disputes, if any, would not materially restore exclusivity.
What formulations are protected by Miraluma patents?
The product’s formulation consists of a nonradioactive kit that is combined with technetium-99m pertechnetate. The formulation includes the ligand and supporting excipients required to produce the injectable radiopharmaceutical.
Historical protection could cover:
- The sestamibi ligand or related coordination chemistry.
- Kit composition.
- Reconstitution procedures.
- Stability and radiochemical purity.
- Imaging methods.
- Packaging and preparation systems.
These categories are no longer sufficient to create a durable commercial moat. Competitors can supply equivalent kits under their own approvals, provided they satisfy FDA chemistry, manufacturing and controls requirements.
What litigation affects Miraluma?
There is no widely recognized current patent litigation that materially constrains Miraluma’s market. The litigation profile is substantially lower than for high-revenue branded drugs with active formulation or method-of-use patents.
Potential disputes in this category would more likely involve:
- Contract manufacturing.
- Supply agreements.
- Radioisotope allocation.
- Product quality or sterility.
- Hospital purchasing contracts.
- Trademark or brand ownership.
- Regulatory compliance.
These issues can affect individual suppliers without recreating product-level exclusivity.
What is the competitive landscape for technetium Tc 99m sestamibi?
Miraluma competes in two markets: the direct sestamibi market and the broader myocardial perfusion imaging market.
Direct and near-direct competitors
| Competitor |
Active technology |
Competitive position |
| Generic technetium Tc 99m sestamibi |
Same active imaging complex |
Direct price and supply competitor |
| Cardiolite |
Technetium Tc 99m sestamibi |
Historical branded reference product |
| Technetium Tc 99m tetrofosmin |
Alternative myocardial perfusion agent |
Direct clinical substitute |
| Thallium-201 |
Older perfusion radiopharmaceutical |
Declining but established alternative |
| PET myocardial perfusion agents |
Rubidium-82 and N-13 ammonia in appropriate settings |
Higher-performance alternative with infrastructure requirements |
| Stress echocardiography |
Nonradioactive imaging |
Procedure-level substitute |
| Coronary CT angiography |
Anatomic imaging |
Competes for diagnostic workup |
| Cardiac MRI |
Functional and structural imaging |
Competes in selected centers |
The principal competitive advantage of sestamibi is installed-base familiarity, broad clinical use and compatibility with established nuclear medicine workflows. Its limitations include dependence on technetium supply, radiation exposure, preparation requirements and competition from PET and anatomic imaging.
How does Miraluma compare with Cardiolite?
Cardiolite has historically had the stronger commercial position because cardiac myocardial perfusion imaging represented the larger and more repeatable procedure market. Miraluma’s association with breast imaging addressed a narrower and more competitive clinical niche.
| Factor |
Miraluma |
Cardiolite |
| Primary historical positioning |
Breast imaging |
Myocardial perfusion |
| Market size |
Niche |
Larger cardiac imaging market |
| Brand value |
Limited and declining |
Historically stronger |
| Generic substitution |
High |
High |
| Clinical substitutes |
Mammography, MRI, ultrasound |
PET, CT angiography, stress echo, MRI |
| Current patent leverage |
None of practical significance |
None of practical significance |
| Revenue visibility |
Not separately disclosed |
Usually embedded in imaging-product revenue |
The two brands shared the underlying sestamibi technology but did not have equivalent commercial trajectories. Breast imaging did not provide Miraluma with the same procedure volume or recurring demand as cardiac imaging.
What is the financial trajectory for Miraluma?
Miraluma’s standalone revenue, gross margin and operating profit are not publicly reported in the financial statements of its former owners. Its financial trajectory must therefore be assessed through product lifecycle and portfolio-level disclosures rather than audited product revenue.
Financial lifecycle
| Stage |
Financial characteristics |
| Launch and adoption |
Revenue supported by proprietary positioning and limited competition |
| Expansion |
Cardiac imaging created recurring procedural demand |
| Maturity |
Volume remained meaningful, but pricing and generic competition increased |
| Post-exclusivity |
Revenue migrated toward equivalent products and supplier contracts |
| Current phase |
Mature, lower-margin diagnostic product with limited standalone brand value |
The product’s economic decline was likely driven by unit-price erosion rather than immediate disappearance of clinical demand. Hospitals and radiopharmacies continue to require myocardial perfusion agents, but purchasing decisions are increasingly based on:
- Delivered price.
- On-time radiopharmacy supply.
- Technetium generator access.
- Product availability by geography.
- Preparation reliability.
- Regulatory compliance.
- Integrated imaging portfolios.
Revenue exposure for former owners
Miraluma is unlikely to represent a separately material revenue exposure for Bracco or any successor supplier. The commercial value is more likely captured within broader diagnostic imaging, contrast-media or radiopharmaceutical revenue categories.
For investors, the relevant exposure is not Miraluma alone. It is the supplier’s broader nuclear medicine platform, including:
- Sestamibi and other myocardial perfusion agents.
- PET radiopharmaceuticals.
- Contrast media.
- Imaging equipment partnerships.
- Radiopharmacy distribution.
- Isotope sourcing and logistics.
A standalone valuation based on Miraluma brand revenue would overstate the remaining intellectual-property value.
What manufacturing and supply barriers affect Miraluma?
Manufacturing barriers are more important than patent barriers.
Key operational barriers
Technetium-99m availability
Technetium-99m is obtained from molybdenum-99/technetium-99m generators and must be delivered within a short radioactive half-life window. Supply interruptions can affect procedure scheduling and product availability.
Radiopharmacy logistics
The product must be prepared, quality-checked and distributed within a constrained time period. Local or regional radiopharmacy capacity affects market access.
Sterility and quality control
Radiopharmaceutical kits require validated aseptic processing and radiochemical testing. Failures can produce recalls, procedure cancellations or regulatory action.
Hospital procurement
Hospitals often buy through group purchasing organizations, integrated delivery networks and radiopharmacy contracts. A supplier may lose share without a patent challenge if it cannot match price, reliability or delivery coverage.
Regulatory compliance
Manufacturers must comply with FDA requirements, state pharmacy rules, current good manufacturing practice standards and radioactive-material controls. These requirements slow entry but do not provide Miraluma-specific exclusivity.
What generic launch risks exist for Miraluma?
Generic launch risk is already realized rather than prospective. The market has moved beyond the initial generic-entry phase.
Current risks to any Miraluma-linked commercial franchise include:
- Continued price compression.
- Product substitution by other sestamibi suppliers.
- Hospital tender losses.
- Technetium shortages.
- Shift from SPECT to PET imaging.
- Broader adoption of coronary CT angiography.
- Declining use of breast-specific sestamibi imaging.
- Manufacturing deviations or supply interruptions.
- Consolidation among radiopharmacy providers.
The risk of a sudden patent-driven generic launch is low because the relevant exclusivity has already expired. The risk of gradual share loss and margin compression is high.
How does Miraluma compare with newer imaging technologies?
Sestamibi remains clinically relevant where SPECT infrastructure is established and PET access is limited. PET can offer improved image quality and shorter protocols in appropriate settings, but requires expensive equipment and reliable tracer supply.
| Technology |
Strength |
Limitation relative to sestamibi |
| Sestamibi SPECT |
Broad installed base and familiar workflow |
Lower resolution and isotope dependence |
| Tetrofosmin SPECT |
Alternative SPECT agent |
Similar isotope and workflow constraints |
| Rubidium-82 PET |
Fast imaging and strong diagnostic performance |
Requires PET equipment and generator infrastructure |
| Coronary CT angiography |
Anatomic coronary assessment |
Different clinical question; contrast and radiation considerations |
| Stress echocardiography |
No radiopharmaceutical required |
Operator and image-quality dependence |
| Cardiac MRI |
High functional and tissue characterization value |
Limited availability and higher operational complexity |
What is the geographic coverage of Miraluma?
The product’s commercial reach has historically depended on regulatory approvals and radiopharmacy distribution rather than global patent exclusivity. Geographic performance varies with:
- National nuclear medicine infrastructure.
- Technetium generator availability.
- Reimbursement for SPECT procedures.
- Local manufacturing and import rules.
- Hospital concentration.
- Availability of PET and cardiac CT.
The United States remains commercially important because of its large installed base of nuclear medicine facilities, but Europe and other developed markets also have established technetium-based imaging networks. Emerging markets may have lower product penetration because isotope logistics and nuclear medicine equipment are less developed.
Key Takeaways
- Miraluma is a legacy technetium Tc 99m sestamibi diagnostic product, not a growth-stage pharmaceutical.
- Its principal economic market is myocardial perfusion imaging; breast imaging is a smaller historical niche.
- Core patents and regulatory exclusivity have expired.
- No current biosimilar pathway applies because Miraluma is not a biologic.
- Paragraph IV litigation is not a material current driver of the product’s market.
- Competitive pressure comes from generic sestamibi suppliers, tetrofosmin, PET, cardiac CT, stress echocardiography and cardiac MRI.
- Standalone Miraluma revenue is not publicly disclosed by former owners or current imaging companies.
- Remaining value is concentrated in supply reliability, radiopharmacy logistics, hospital contracts and broader diagnostic-imaging portfolios.
- The financial trajectory is mature to declining for the brand, although the underlying cardiac-imaging procedure market remains active.
- Manufacturing and isotope supply constraints are more relevant than patent barriers.
FAQs About Miraluma Market and Exclusivity
Is Miraluma still marketed under its original brand name?
Miraluma is primarily a legacy brand reference. Current clinical supply is more likely to be encountered through technetium Tc 99m sestamibi products, generic suppliers or related commercial brands.
Is Miraluma the same drug as Cardiolite?
Both products are associated with technetium Tc 99m sestamibi, but the brands had different historical positioning. Cardiolite was principally associated with myocardial perfusion imaging, while Miraluma was associated with breast imaging.
Can a generic company launch technetium Tc 99m sestamibi?
Yes. The core exclusivity period has expired, and equivalent sestamibi products can compete subject to FDA approval, manufacturing controls, radiopharmacy requirements and isotope availability.
Does Miraluma have biosimilar competition?
No. Biosimilars apply to biological products. Miraluma is a radiopharmaceutical small-molecule imaging product and is addressed through conventional drug and radiopharmaceutical regulatory pathways.
What is the biggest commercial risk for Miraluma suppliers?
The largest risks are price erosion, hospital-contract losses, technetium supply disruption and substitution by PET or nonnuclear cardiac-imaging modalities. Patent expiration is no longer the main commercial issue.
References
- U.S. Food and Drug Administration. (n.d.). MIRALUMA: Technetium Tc 99m sestamibi kit prescribing information. Drugs@FDA.
- Bracco Group. (2002). Bracco acquires Bristol-Myers Squibb medical imaging business. Bracco corporate transaction materials.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- International Atomic Energy Agency. (2023). Technetium-99m supply and nuclear medicine production. IAEA.
- American Society of Nuclear Cardiology. (2023). Guidelines and clinical standards for myocardial perfusion imaging. ASNC.
